Lenvatinib and Depth of Response in Advanced uHCC: Insights From REFLECT

Opinion
Video

An expert discusses how recent analyses from the REFLECT trial in unresectable hepatocellular carcinoma (uHCC) demonstrate that both achieving objective response and greater depth of response correlate with improved survival outcomes. The depth of response serves as a potentially valuable early biomarker for prognosis and treatment decisions, with deeper responses associated with better overall survival among responders.

Video content above is prompted by the following:

  • What role do the overall response and depth of response play in guiding treatment decisions for advanced uHCC?
  • Review recent evidence from REFLECT looking at characterization of tumor response.
  • Please discuss the clinical implications from the best overall response, depth of response, and overall survival among responders’ data.
  • What are your thoughts on looking at the depth of response as a marker for clinical outcomes?
Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

Jordyn Sava
March 3rd 2025
Article

A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

Read More

Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen

Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

Jordyn Sava
January 24th 2025
Article

The CheckMate 9DW study demonstrated the efficacy and manageable safety of first-line nivolumab plus ipilimumab in patients with unresectable hepatocellular carcinoma.

Read More

TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

Russ Conroy
January 24th 2025
Article

TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.

Read More

Amezalpat Gains FDA Orphan Drug Status in HCC

Amezalpat Gains FDA Orphan Drug Status in HCC

Jordyn Sava
January 8th 2025
Article

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy and safety with atezolizumab and bevacizumab in frontline treatment.

Read More

Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

Targeted Oncology Staff
December 21st 2024
Article

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.

Read More